Gland Pharma Ltd has reported total income of Rs.1215.73 crores during the period ended June 30, 2021 as compared to Rs.934.96 crores during the period ended March 31, 2021. The company reported total income of Rs.916.28 crores during the period ended June 30, 2020.

Gland Pharma has posted net profit of Rs.350.65 crores for the period ended June 30, 2021 as against net profit of Rs.260.40 crores for the period ended March 31, 2021. It posted net profit of Rs.313.59 crores for the period ended June 30, 2020.

Commenting on the results, Srinivas Sadu, MD & CEO of Gland Pharma said "In spite of the challenges from the second wave of COVID in the country, in terms of manpower availability and supply chain bottlenecks, Gland Pharma has managed to deliver strong quarterly results.

“The revenue for the quarter stood at Rs 11,53.9 crore, which is a Y-o-Y revenue growth of 31%, with a PAT margin of 29%, which is Rs 350.7 crore. Our execution capabilities, be it uninterrupted commercial supplies, project commissioning or new product launches, is what underpins our strong performance in this quarter.

It was an important milestone for the company to launch our first set of Penem products for the US market during the quarter. The dedicated suite for vaccine drug product fill finish is now ready for vaccine commercial production, while the tech transfer for the drug substance manufacturing is ongoing. We continue to support the nation by ramping up production of essential COVID drugs."